MedTrace Logo

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women

NCT00141544 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2008-04-11

No results posted yet for this study

Summary

To determine whether treatment with ESTRATEST® Tablets is superior to treatment with esterified estrogens tablets

Conditions

Interventions

DRUG

esterified estrogens 1.25 mg and methyltestosterone 2.5 mg

ESTRATEST® administered orally QD

DRUG

Esterified estrogens 1.25 mg

Esterified estrogens 1.25 mg administered orally QD

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Director Solvay · Solvay Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2007-04-30
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00141544 on ClinicalTrials.gov